Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PegIntron and Rebetol in Hepatitis C with Compensated Cirrhosis
NCT00811967Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Feb 2003
- Primary completion
- May 2006
01
Overview
Phase 3, randomised, open-label trial of peginterferon alfa-2b in hepatitis C virus infection (2 arms), sponsored by Merck & Co. Primary endpoint: Sustained Virologic Response. Started Feb 2003; status: terminated.
02
Drugs
peginterferon alfa-2b
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT00811967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00811967.